In this study, we analyzed primary ER+ breast cancers and metastases across multiple sites, including lymph nodes, liver, bone, adrenal gland, and subcutaneous (Fig. 1a), to provide a broader view of TME alterations. This evidence concerns the gene ESR1 and breast carcinoma.